Aigen Investment Management LP Has $490,000 Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Aigen Investment Management LP cut its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 14.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,645 shares of the company’s stock after selling 432 shares during the period. Aigen Investment Management LP’s holdings in Inspire Medical Systems were worth $490,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC purchased a new position in Inspire Medical Systems during the fourth quarter valued at approximately $4,124,000. M&T Bank Corp grew its position in Inspire Medical Systems by 9.2% during the fourth quarter. M&T Bank Corp now owns 3,526 shares of the company’s stock valued at $654,000 after purchasing an additional 298 shares in the last quarter. Keybank National Association OH grew its position in Inspire Medical Systems by 0.3% during the fourth quarter. Keybank National Association OH now owns 200,759 shares of the company’s stock valued at $37,217,000 after purchasing an additional 586 shares in the last quarter. Cornerstone Investment Partners LLC purchased a new position in Inspire Medical Systems during the fourth quarter valued at approximately $200,000. Finally, Charles Schwab Investment Management Inc. grew its position in Inspire Medical Systems by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 296,207 shares of the company’s stock valued at $54,911,000 after purchasing an additional 15,042 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Inspire Medical Systems

In related news, insider Randy Ban sold 25,584 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This represents a 77.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the transaction, the chief technology officer now owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,225 shares of company stock worth $4,806,530 in the last ninety days. 4.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $220.00 to $255.00 in a research report on Wednesday, November 20th. Wells Fargo & Company decreased their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Robert W. Baird decreased their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research report on Tuesday, February 11th. Piper Sandler decreased their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus decreased their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.82.

Inspire Medical Systems Trading Up 4.7 %

NYSE INSP opened at $183.34 on Friday. The company has a fifty day simple moving average of $187.08 and a 200 day simple moving average of $192.70. The company has a market cap of $5.44 billion, a P/E ratio of 105.98, a P/E/G ratio of 2.86 and a beta of 1.48. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.